Hypercalcemia occurs in 10% to 20% of those with advanced cancer. It is considered an oncologic emergency. Presenting symptoms include common gastrointestinal symptoms that may be difficult to differentiate from tumor or treatment-related symptoms. These include nausea, vomiting, and constipation. As levels increase or if development is rapid, neuropsychiatric symptoms such as delirium can develop. Untreated it will lead to coma and death. Current preferred therapies are the bisphosphonate agents, zoledronate and pamidronate with saline rehydration.
FojoAT. Metabolic emergencies. In: DeVitaVTLawrenceTSRosenberySA, eds. Cancer: Principles and Practice of Oncology. 8th ed. Philadelphia, PA: Lippincott, Williams and Wilkins; 2008:2451–2453.
2.
BesarbACaroJF. Mechanisms of hypercalcemia in malignancy. Cancer. 1978;41(6):2276–228.
3.
PottsJohn T.Jr. ” Diseases of the parathyroid gland and other hyper- and hypocalcemic disorders. In: FauciASBraunwaldEKasperDLHauserSLLongoDLJamesonJLLoscalzoJ, eds. Harrison’s Principles of Internal Medicine17e: http://www.accessmedicine.com/content.aspx?aID=2903146. Accessed June 17, 2011.
4.
StewartAF. Clinical practice: hypercalcemia associated with cancer. N Engl J Med. 2005;352(4):373–379.
5.
de WitsCletonEJ. Hypercalcemia in patients with breast cancer: a survival study. J Cancer Res Clin Oncol. 1994;120(10):610–614.
6.
RalstonSHGallacherSJPatelUCampbellJBoyleIT. Cancer-associated hypercalcemia: morbidity and mortality. Ann Internal Med. 1990;112(7):499–504.
7.
PenelNDewasSDoutrelantPSlisantSYazganpanahYAdenisA. Cancer-associated hypercalcemia treated with intravenous diphosphonates: a survival and prognostic factor analysis. Support Care Cancer. 2008;16(4):387–392.
8.
MajorPLortholaryAHonJZoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized controlled clinical trials. J Clin Oncol. 2001;19(2):558–576.
9.
Leyland-JonesB. Treatment of cancer-related hypercalcemia: the role of gallium nitrate. Semin Oncol. 2003;30(2 suppl 5):13–19.
10.
CvitkovicFArmandJPTubiana-HulinMRossiJFWarrellRP. Randomized, double blind, phase II trial of gallium nitrate compared with pamidronate for acute control of cancer-related hypercalcemia. Cancer J. 2006;12(1):47–53.
11.
GurneyHGrillVMartinTJ. Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcaemia. Lancet. 1993;341(8861):1611–1613.
12.
WallsJRatcliffeWAHowellABundredNJ. Response to intravenous bisphosphonates in hypercalcaemic patients with and without bone metastases: the role of parathyroid hormone-related protein. Br J Cancer. 1994;70(1):169–172.
13.
Leyland-JonesB. Pharmokinetics and therapeutic index of gallium nitrate. Semin Oncol. 1991;18(4):16–20.
14.
TruongBUdeB EdwardesMDPapavasiliouVGoltzmanDKremerR. Parathyroid hormone –related peptide and survival of patient with cancer and hypercalcemia. Am J Med. 2003;115(2):115–121.
15.
LeGrandSBLeskuskiDZamaI. Narrative review: furosemide for hypercalcemia: an unproven yet common practice. Ann Internal Med. 2008;149(4):259–263.
16.
BodyJJ. Current and future directions in medical therapy: hypercalcemia. Cancer. 2000;88(12 suppl):3054–3058.
17.
MundyGRGuiseTA. Hypercalcemia of malignancy. Am J Med. 1997;103(2):134–145.
18.
MarkowitzGSFinePLStackJIToxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int. 2003;64(1):281–289.
19.
ChangJTGreenLBeitzJ. Renal failure with the use of zoledronic acid. N Engl J Med. 2003;349(17):1676–1679.
20.
MachadoCEFlombaumCD. Safety of pamidronate in patients with renal failure and hypercalcemia. Clin Nephrol. 1996;45(3):175–179.
